However, for the subgroup of patients with baseline cardiovascular disease, point estimates indicated a lower incidence of ADRD with TNF inhibitors in 2 of 4 analyses (analysis 1: HR, 0.76 [95% CI, 0.50-1.16]; analysis 2: HR, 0.74 [95% CI, 0.56-0.99]; analysis 3: HR. This evidence concerns the gene TNF and cardiovascular disorder.